Equities Analysts Offer Predictions for DRUG Q3 Earnings

Bright Minds Biosciences Inc. (NASDAQ:DRUG - Free Report) - Research analysts at HC Wainwright reduced their Q3 2025 earnings per share (EPS) estimates for shares of Bright Minds Biosciences in a report released on Thursday, May 22nd. HC Wainwright analyst P. Trucchio now forecasts that the company will post earnings per share of ($0.76) for the quarter, down from their prior estimate of ($0.73). HC Wainwright currently has a "Buy" rating and a $85.00 target price on the stock. The consensus estimate for Bright Minds Biosciences' current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Bright Minds Biosciences' Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($2.12) EPS, Q1 2026 earnings at ($0.98) EPS, Q2 2026 earnings at ($1.30) EPS, Q3 2026 earnings at ($1.58) EPS, Q4 2026 earnings at ($1.84) EPS, FY2026 earnings at ($5.78) EPS, FY2027 earnings at ($5.89) EPS, FY2028 earnings at ($5.96) EPS and FY2029 earnings at ($1.75) EPS.

Several other equities analysts have also weighed in on DRUG. Cowen started coverage on shares of Bright Minds Biosciences in a report on Tuesday, May 13th. They set a "buy" rating for the company. Cantor Fitzgerald raised shares of Bright Minds Biosciences to a "strong-buy" rating in a report on Tuesday, May 13th. Wall Street Zen downgraded shares of Bright Minds Biosciences from a "hold" rating to a "sell" rating in a research report on Thursday, May 22nd. Chardan Capital restated a "buy" rating and set a $80.00 target price on shares of Bright Minds Biosciences in a research report on Wednesday, May 21st. Finally, TD Cowen initiated coverage on Bright Minds Biosciences in a research note on Tuesday, May 13th. They issued a "buy" rating for the company. One analyst has rated the stock with a sell rating, six have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $83.25.

Bright Minds Biosciences Trading Down 5.4%

NASDAQ DRUG traded down $1.57 on Monday, hitting $27.44. 39,598 shares of the company's stock traded hands, compared to its average volume of 825,050. The firm's 50-day moving average price is $32.07 and its two-hundred day moving average price is $35.80. The firm has a market capitalization of $193.29 million, a PE ratio of -161.40 and a beta of -5.32. Bright Minds Biosciences has a 1-year low of $0.93 and a 1-year high of $79.02.

Bright Minds Biosciences (NASDAQ:DRUG - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.10.

Hedge Funds Weigh In On Bright Minds Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC acquired a new position in shares of Bright Minds Biosciences during the 4th quarter valued at about $18,392,000. RA Capital Management L.P. acquired a new position in Bright Minds Biosciences in the 4th quarter valued at about $16,599,000. Vivo Capital LLC acquired a new position in Bright Minds Biosciences in the fourth quarter valued at approximately $9,062,000. Adage Capital Partners GP L.L.C. grew its position in Bright Minds Biosciences by 50.9% in the first quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company's stock worth $7,214,000 after acquiring an additional 67,500 shares during the period. Finally, Millennium Management LLC raised its position in Bright Minds Biosciences by 376.9% in the first quarter. Millennium Management LLC now owns 192,557 shares of the company's stock valued at $6,946,000 after purchasing an additional 152,178 shares during the period. 40.52% of the stock is owned by hedge funds and other institutional investors.

Bright Minds Biosciences Company Profile

Bright Minds Biosciences Inc, a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder.